Evidence map›Paper›PMID 34952974›Full record

ArticleClinical cardiology2022

Use of oral anticoagulants and its associated factors among nonvalvular atrial fibrillation patients with new-onset acute ischemic stroke: A report from the China Atrial Fibrillation Registry study.

Jing-Rong Wang, Xin Du, Jian-Zeng Dong, San-Shuai Chang, Chao Jiang, Cai-Hua Sang, De-Yong Long, Ri-Bo Tang, Hai-Bin Zhang, Jin-Cheng Guo and 3 more

Open access · goldAbstract read
In one paragraph

Article in Clinical cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Jing-Rong WangDepartment of Cardiology, National Clinical Research Centre for Cardiovascular Diseases, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine for Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-1910-3961
Xin DuDepartment of Cardiology, National Clinical Research Centre for Cardiovascular Diseases, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine for Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Jian-Zeng DongDepartment of Cardiology, National Clinical Research Centre for Cardiovascular Diseases, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine for Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
San-Shuai ChangDepartment of Cardiology, National Clinical Research Centre for Cardiovascular Diseases, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine for Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Chao JiangDepartment of Cardiology, National Clinical Research Centre for Cardiovascular Diseases, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine for Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0003-1138-7960
Cai-Hua SangDepartment of Cardiology, National Clinical Research Centre for Cardiovascular Diseases, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine for Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
De-Yong LongDepartment of Cardiology, National Clinical Research Centre for Cardiovascular Diseases, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine for Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Ri-Bo TangDepartment of Cardiology, National Clinical Research Centre for Cardiovascular Diseases, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine for Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0003-2812-1827
Hai-Bin ZhangDepartment of Cardiology, Cardiovascular Center, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Jin-Cheng GuoDepartment of Cardiology, Cardiovascular Center, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Yu-Mei WenDepartment of Cardiology, Cardiovascular Center, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Liu HeDepartment of Cardiology, National Clinical Research Centre for Cardiovascular Diseases, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine for Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Chang-Sheng MaDepartment of Cardiology, National Clinical Research Centre for Cardiovascular Diseases, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine for Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-5387-5957
Capital Medical University · CNBeijing Luhe Hospital Affiliated to Capital Medical University · CN

Funding

The National Key Research and Development Program of China 2018YFC1312501The National Key Research and Development Program of China 2020YFC2004803The National Natural Science Foundation of China 82103904
6 · The paper itself

Abstract

backgroundThe adherence of oral anticoagulant (OAC) therapy among nonvalvular atrial fibrillation (NVAF) patients with acute ischemic stroke (AIS) in China during recent years was unclear, and the possible factors that influenced the initiation and persistent use of OAC were needed to be explored.

methodsA total of 1085 NVAF patients, who experienced new-onset and nonfatal AIS from August 2011 to December 2020 during follow-ups in the China Atrial Fibrillation Registry (China-AF), were enrolled. Information including patients' demographic characteristics, medical history, medication usage, which were collected before and after the index stroke, were used in the analysis.

resultsOAC was initiated in 40% (434/1085) NVAF patients within 3 months after new-onset AIS. High-reimbursement-rate insurance coverage (odds ratio [OR]: 1.51, 95% confidence interval [CI]: 1.03-2.22, p = .036), 3-month-peri-stroke AF episodes (OR: 2.63, 95% CI: 1.88-3.69, p < .001), and pre-stroke OAC usage (OR: 8.92, 95% CI: 6.01-13.23, p < .001), were positively associated with initiation of OAC within 3 months after new-onset AIS, while age (OR: 0.98, 95% CI: 0.96-1.00, p = .024), female (OR: 0.63, 95% CI: 0.44-0.90, p = .012) and higher modified HASBLED score (OR: 0.45, 95% CI: 0.37-0.55, p < .001) were negatively associated with it. Among 3-month-post-stroke OAC users, history of radiofrequency ablation (hazard ratio: 1.65, 95% CI: 1.16-2.35; p = .006) was positively associated with non-persistence of OAC usage.

conclusionsIn China, the proportion of NVAF patients who initiated OAC therapy since new-onset AIS was still low. More efforts are needed on improving patients' adherence to anticoagulant therapy.

Indexed as

Atrial FibrillationBrain IschemiaIschemic StrokeStrokeAdministration, OralAnticoagulantsFemaleHumansRegistriesAnticoagulantsanticoagulant therapyatrial fibrillationstroke

Identifiers

PMID34952974
PMCPMC8799037
OpenAlexW4200168229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.